Colesevelam

Drug Profile

Colesevelam

Alternative Names: Cholestagel; Colesevelam hydrochloride; GT 31104; Lodalis; WelChol

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Daiichi Sankyo Company; Sanofi Genzyme
  • Class Amines; Antihyperglycaemics; Antihyperlipidaemics; Polymers
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 17 Jul 2013 Safety and efficacy data from a phase III trial in Type 2 diabetes mellitus were released by Daiichi Sankyo
  • 29 Feb 2012 Launched for Hypercholesterolaemia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top